Drugs / ARI0002h
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04309981 | May 2020 → Apr 2025 | refractory plasma cell neoplasm | Sara V. Latorre | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06830733 | Apr → Dec 2025 overdue | plasma cell leukemia | Fundacion Clinic per a la Recerca Biomédica | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARI0002h | “We aimed to assess the safety and activity of ARI0002h, a BCMA-targeted CAR T-cell therapy” PMID 37414060 ↗ Jul 2023 |
| Known as | CARTBCMA\_J22.9-h:CD8TM:4-1BB:CD3 | “Other names: CARTBCMA\_J22.9-h:CD8TM:4-1BB:CD3. Adult differentiated autologous T cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric...” NCT06830733 ↗ |
| Modality | Cell therapy | “humanised, BCMA-directed CAR T-cell therapy” PMID 37414060 ↗ Jul 2023 |
| Route | Intravenous | “1.8 × 106 CAR-positive cells per kg intravenously on days 0, 3, and 7” PMID 37414060 ↗ Jul 2023 |
| Target | TNFRSF17 | “anti-BCMA (TNFRSF17) specificity” NCT04309981 ↗ |